What milligram strengths of Clevatess exist?
What milligram strengths of Clevatess exist?
Clevatess is available in a single oral tablet strength of 10 mg. This prescription medication, containing the active ingredient clascoterone, is specifically formulated for treating acne vulgaris in patients 12 years of age and older.
Available Dosage Form
The medication comes as oral tablets that are designed for once-daily administration. Each Clevatess tablet contains 10 mg of clascoterone, which represents the only commercially available strength approved by the FDA.
Standard Dosing Information
The recommended dosage of Clevatess is one 10 mg tablet taken orally once daily, with or without food. This standardized strength simplifies dosing decisions for healthcare providers and ensures consistent therapeutic levels of the active ingredient.
Why Only One Strength?
Pharmaceutical companies typically develop multiple strengths based on clinical trial data and patient needs. Clevatess's single 10 mg strength reflects the optimal therapeutic dose identified during clinical development, providing effective acne treatment while minimizing potential side effects.
Important Considerations
Patients should never split, crush, or chew Clevatess tablets, as this can affect the medication's absorption and effectiveness. The 10 mg strength has been specifically engineered for proper drug release and bioavailability.
Storage and Handling
Clevatess 10 mg tablets should be stored at room temperature, away from moisture and heat. The medication comes in child-resistant packaging to ensure safety.
Clinical Effectiveness
Studies have shown that the 10 mg daily dose of Clevatess provides significant improvement in acne lesions compared to placebo, making it an effective treatment option for eligible patients.
For specific dosing instructions and to determine if Clevatess is right for your acne treatment needs, consult with your dermatologist or healthcare provider. They can provide personalized guidance based on your individual medical history and treatment goals.
Discussion (0)